This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Emergent BioSolutions, Inc.
Drug Names(s): PF-05212374
Description: TRU-015 is a small modular immunopharmaceutical (SMIP) drug candidate. SMIPs represent a novel proprietary biologic compound class that retain Fc mediated effector functions and are smaller than monoclonal antibodies. TRU-015, a SMIP that binds to CD20, depletes B cells in vitro and in animal models. TRU-015 elucidates less complement-dependent cellular cytotoxicity (CDCC) than other anti-CD20 compounds, which correlates to decreased infusion-related reactions.
Deal Structure: In January 2006, Wyeth Pharmaceuticals and Trubion Pharmaceuticals announced that they formed a strategic alliance for the discovery, development and commercialization of novel biopharmaceutical products to treat inflammatory disease and cancer. The alliance utilizes Trubions proprietary Small Modular Immunopharmaceutical (SMIP) technology. As part of the alliance, Wyeth and Trubion will collaborate on the development and commercialization of CD20-targeted therapies including TRU-015. As part of the transaction, Trubion received an initial $40 million payment. Trubion will retain an option to co-promote CD20-targeted therapies in the United States for certain indications. Wyeth will be responsible for future development and commercialization costs for the alliance. The agreement also provides for additional payments to Trubion upon the achievement of certain development milestones, royalties on product sales, and a stock purchase when Trubion makes a qualified initial public...See full deal structure in Biomedtracker
Partners: Pfizer Inc.
Additional information available to subscribers only: